Intended for licensed healthcare professionals located in the United Kingdom and Republic of Ireland only

UK prescribing information ROI prescribing information UK SmPC ROI SmPC Report an adverse event
ESMO guideline recommendations FGFR2 fusion testing
About PEMAZYRE
Efficacy Safety FAQs
Dosing and administration Request a meeting Stay informed Resources

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events.

Frequently Asked Questions

shared.diamonds shared.diamonds

Search or browse the categories...

Search icon
Adverse reactions
Dosing and administration
Efficacy data
Pharmacodynamics and pharmacokinetics
Pregnancy and breastfeeding
Prescribing information
Product details and authorisation
Special warnings and precautions for use
Storage

Or

Report an adverse event
Summary of Product Characteristics (SmPC) – United Kingdom Summary of Product Characteristics (SmPC) – Republic of Ireland

Can't find the answers you need?

Contact us
Privacy Policy Cookie Policy Terms of Use If you would like to request further medical information, please visit:
https://www.incyteglobalmedicalinformation.com/
Marketing authorisation holder:
United Kingdom
Incyte Biosciences UK Ltd,
First Floor Q1, The Square,
Randalls Way, Leatherhead,
KT22 7TW, UK

Republic of Ireland
Incyte Biosciences Distribution B.V.
Paasheuvelweg 25,
1105 BP Amsterdam, Netherlands

UNITED KINGDOM
Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Incyte by calling 00‑800‑0002‑7423.

REPUBLIC OF IRELAND
Adverse events should be reported.Reporting forms and information can be found at HPRA Pharmacovigilance: www.hpra.ie. Adverse events should also be reported to Incyte immediately by phoning the Toll-free phone number 1800‑456‑748.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

This medicinal product has been authorised under a 'conditional approval' scheme. This means that further evidence on this medicinal product is awaited.

IE/PEMA/P/25/0010
Date of preparation: January 2025
Developed and funded by Incyte Biosciences International Sàrl.
© 2025, Incyte. All rights reserved.
PEMAZYRE, the PEMAZYRE logo and the Incyte logo are registered trademarks of Incyte.

Back to top

External link disclaimer

Intended for licensed healthcare professionals located in the United Kingdom and Republic of Ireland only.

You are now leaving the Incyte PEMAZYRE website. This link will take you to a site that is not owned or maintained by Incyte. Incyte is not responsible for the information contained on third⁠–⁠party sites. Would you like to continue?

Yes No

Report an adverse event

Caution

Intended for licensed healthcare professionals located in the United Kingdom and Republic of Ireland only.

You are now leaving the Incyte PEMAZYRE website. This link will take you to the site https://www.incyte.com, owned by Incyte Corporation and managed by the company. Would you like to continue?

Yes No

Report an adverse event

Want to be kept up to date with the latest news in oncology? Complete this quick form to receive relevant information from Incyte

Yes please No thanks